サンプル依頼リスト カート
  • English
  • Korean
表紙：末梢動脈疾患用デバイスの世界市場-2023年～2030年
市場調査レポート
商品コード
1352141

末梢動脈疾患用デバイスの世界市場-2023年～2030年

Global Peripheral Artery Disease Device Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
末梢動脈疾患用デバイスの世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

末梢動脈疾患（PAD）患者では下肢動脈灌流が低下しており、"循環不良"と呼ばれています。PAD患者の大部分では、動脈硬化性プラークが動脈内腔を制限し、遠位四肢への血流を制限しています。血流の低下は、活動中の下肢筋肉の一時的な虚血により、歩行時に大腿部やふくらはぎの不快感をもたらします。

PADは全身性アテローム性動脈硬化症の指標となるため、無症状の人にPADの診断を下すことは臨床的に大きな影響を与えます。PADの患者は心筋梗塞の既往のある患者と同等の心血管系の脅威を持ち、虚血性心筋梗塞につながる可能性があるため、動脈硬化の長期的な生存を高めるために積極的な脅威因子の変換が必要です。

末梢動脈疾患の症例の増加、合併、買収、製品イントロダクションなどの市場開拓、認知度の高まりなどが、予測期間における世界の末梢動脈疾患デバイス市場の成長を後押しすると予想されます。さらに、末梢動脈疾患デバイスにおける研究活動の活発化、技術進歩、資金提供なども、予測期間における世界市場の成長に貢献すると期待されています。

ダイナミクス

末梢動脈疾患の高い有病率

末梢動脈疾患の高い有病率は、予測期間中の世界市場の成長を後押しすると予想されます。例えば、NIHによると、PADは全世界で2億人以上の成人に影響を与え、70歳以上ではPADの発生率は20％にまで上昇します。PADは従来、男性に影響を与える疾患とされてきましたが、PADの大部分は老年期の男性でも女性でも同様だと考えられます。

PAD患者の大多数は定型的な跛行の徴候を示さないため、予備的な医療環境におけるPADの過小診断は重大な問題である可能性があります。さらに、米国心臓協会によると、末梢動脈疾患（PAD）の罹患率と罹患率は増加の一途をたどっており、世界中で2億人以上がこの診断を受けながら生活しています。末梢動脈疾患はかなりの罹患率と死亡率に関係しており、冠動脈疾患の脅威と一致すると考えられています。

また、CDCによると、米国では40歳以上の約650万人がPADを患っています。女性も男性もPADの影響を受けますが、アフリカ系アメリカ人はPADの脅威が高いです。住民の高齢化により、末梢動脈疾患の割合が増加しています。さらに、心血管造影・インターベンション学会（Society for Cardiovascular Angiography &Interventions）は、米国で1,000万人以上が末梢動脈疾患（PAD）の影響を受けていると推定しています。

デバイスの進歩の増加

デバイスの進歩の増加も、予測期間中の世界の末梢動脈疾患デバイス市場の成長に寄与すると予想されます。例えば、末梢動脈疾患に対する経皮的治療は、新しいアプローチと先進的なデバイスによって進歩し続けています。ガイドラインで推奨される治療は心血管系の罹患率や死亡率に影響を及ぼしていますが、血管内インターベンションは四肢の痛みを軽減し、生活のグレードを高め、跛行のある人の歩行寿命を延ばし、重症虚血肢の切断率を低下させることが実証されています。

さらに、薬剤溶出ステントや薬剤コーティングバルーンなどの新しいデバイスは、中程度の長さの病変に対する開存性を向上させました。病変を叩いたり、連鎖したプラークを下げたり変化させたりする新しい補助器具も設計されています。さらに、血管内超音波などの機器を用いた下肢血管内治療のメカニズム的解釈の向上により、大腿膝窩動脈セグメントでは適切なステントサイズの選択、脛骨動脈ではより広範なバルーン径の選択が求められていることが強調されています。

他の治療法の利用可能性

薬物療法や外科手術を含む他の治療オプションが利用可能であるため、予測期間中の世界市場の成長は鈍化すると予想されます。例えば、末梢動脈疾患は、コレステロール値を下げるスタチンや血栓を予防するクロピドグレル（プラビックス）などの薬物療法で治療することができます。外科的治療にはバイパス手術があり、外科医は体の別の部位から採取した健康な血管や人工血管を利用して、詰まった動脈を迂回するルートを作ります。

血栓が動脈を塞いでいる場合には、血栓溶解療法が提案される場合もあり、血栓を溶解する薬剤を直接動脈に投与することもあります。このように、末梢動脈疾患に対する他の治療オプションが可能であることが、予測期間において世界の末梢動脈疾患デバイス市場の成長を鈍化させると予想されます。

心臓専門医の労働力不足

循環器専門医の労働力不足は、予測期間中の世界の末梢動脈疾患デバイス市場の成長を妨げると予想されます。例えば、米国心臓病学会（American College of Cardiology Foundation）によると、増え続ける患者の要求を満たすのに十分な臨床医がいないため、心臓病学の専門領域は懸念の危機に瀕しています。同様に、欧州心臓病学会によると、高所得国の人口100万人当たりの循環器専門医数の中央値は99.0人であるのに対し、中所得国では61.1人です。

さらに、インド心臓専門医協会（CSI）によると、人口13億人のインドに心臓専門医は5500人しかおらず、人口3万人に対して心臓専門医は1人しかいないです。また、米国医科大学協会（AAMC）の最近の調査によると、2034年までにこの国では3万7000人から12万4000人の医師が不足すると予測されています。その内訳は、プライマリ・ケア医が17,000人から48,000人、循環器専門医が3,000人から13,000人です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 末梢動脈疾患の高い有病率
      • デバイスの進歩の増加
    • 抑制要因
      • 他の治療法の利用可能性
      • 心臓専門医の労働力不足
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 特許分析
  • 技術動向
  • エンドユーザー動向
  • SWOT分析
  • ロシア・ウクライナ戦争の影響
  • DMIの見解

第6章 COVID-19分析

第7章 タイプ別

  • 機能性末梢動脈疾患
  • 器質性末梢動脈疾患

第8章 デバイスタイプ別

  • 血管ステント
  • バルーンカテーテル
  • ガイドワイヤー
  • アテレクトミーデバイス
  • 下大静脈フィルター
  • 塞栓防止装置
  • その他

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター
  • 学術研究センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • EMS Handels Gesellschaft m.b.H.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • BECTON, DICKINSON AND COMPANY
  • Medtronic
  • Allengers
  • EB NEURO S.P.A.
  • Shenzhen Delica Medical Equipment Co., Ltd.
  • Micromed Group
  • NIHON KOHDEN CORPORATION
  • Cadwell
  • Natus Medical Incorporated

第13章 付録

目次
Product Code: MD6865

Overview

Patients with peripheral arterial disease (PAD) include reduced lower extremity arterial perfusion referred to as "poor circulation." In the majority of PAD patients, atherosclerotic plaques limit the arterial flow lumen restricting blood flow to the distal extremity. Decreased blood flow can yield thigh or calf discomfort with walking owing to temporary ischemia of the leg muscles during activity.

Producing the diagnosis of PAD in asymptomatic individuals has a substantial clinical influence since PAD serves as an attribute for systemic atherosclerosis. Individuals with PAD hold an equal cardiovascular threat to patients with prior myocardial infarction and demand aggressive threat factor transformation to enhance their long-term survival with atherosclerosis as it can lead to ischemic cardiac stroke.

The growing cases of peripheral arteial disease, market developments including mergers, acquisitions, products introductions among others, growing awareness among other factors are expected to boost the global peripheral artery disease device market growth in the forecast period. Further, the growing research activities, technological advancements and with fundings in peripheral artery disease device are also expected to contribute to the global market growth in the forecast period.

Dynamics

High Prevalence of Peripheral Artery Disease

The high prevalence of peripheral artery disease is expected to boost the global market growth during the forecast period. For instance, according to NIH, PAD impacts more than 200 million adults globally, and the incidence of PAD advances to as elevated as 20% in individuals above the age of 70. Although PAD has conventionally been referred to as a condition impacting males, the preponderance of PAD seems to be similar in geriatric males and females.

The under-diagnosis of PAD in the preliminary care setting may be a substantial problem, as the majority of patients with PAD do not exhibit the stereotypical claudication signs. Moreover, according to the American Heart Association, the incidence and preponderance of peripheral artery disease (PAD) persist to advance with above 200 million people living with this diagnosis globally. It has been related to substantial morbidity and mortality, and it is thought to be a coronary artery condition threat matching.

Also, according to the CDC, approximately 6.5 million individuals age 40 and older in the U.S. carry PAD. Both females and males are impacted by PAD whereas, African Americans have an advanced threat of PAD. The aging inhabitants, which lead to an upsurge in the preponderance of peripheral artery disease. Further, the Society for Cardiovascular Angiography & Interventions estimated that over 10 million individuals in the United States are impacted by peripheral arterial disease (PAD).

Increasing Device Advancements

The increasing device advancements are also expected to contribute to the global Peripheral Artery Disease Device market growth during the forecast period. For instance, the percutaneous treatments for peripheral artery conditions persist to advance with new approaches and advanced devices. Although guidelines-recommended treatments have influenced cardiovascular morbidity and mortality, endovascular interventions have been demonstrated to lower limb pain, enhance the grade of life, extend walking span for those with claudication, and lower amputation rates among those with critical limb ischemia.

Moreover, novel devices like drug-eluting stents and drug-coated balloons have enhanced patency for moderate-length lesions, whereas others permit therapy of heavily calcified and tortuous features. New adjunctive instruments to strike lesions and lower or alter linked plaque have even been designed. Further, a better mechanistic interpretation of lower extremity endovascular therapy utilizing devices like intravascular ultrasound has emphasized the demand for adequate stent size selection for the femoropopliteal arterial segments and more extensive balloon diameters for the tibial arteries.

Availability of other Treatment Options

The availability of other treatment options including medications and surgery is expected to slow the global market growth during the forecast period. For instance, peripheral artey disease can be treated with medication which may include statins to lower cholesterol levels, and clopidogrel (Plavix) to prevent blood clots, among others. The surgical treatment includes Bypass surgery in which the surgeon constructs a route around the clogged artery utilizing either a healthy blood vessel from another part of the body or a synthetic one.

In some cases Thrombolytic therapy is suggested if a blood clot is precluding an artery, a clot-dissolving drug may be administered directly into the involved artery. This avability of other treatment option for peripheral artey disease are expected to slow the global Peripheral Artery Disease Device market growth in the forecast period.

Cardiologists Workforce Shortage

The cardiologists' workforce gap is expected to hamper the global Peripheral Artery Disease Device market growth during the forecast period. For instance, according to the American College of Cardiology Foundation with not sufficient clinicians available to satisfy the requirements of an ever-growing patient population, the cardiology specialty domain is on the cusp of a concern. Similarly, according to the European Society of Cardiology in high-income nations, the median number of cardiologists per million inhabitants was 99.0 compared with 61.1 in middle-income nations.

Further, according to the Cardiologists Society of India (CSI), there are merely 5500 cardiologists in the country with a population of 1.3 billion, and there is only one cardiologist for the 30, 000 inhabitants in the nation. Again, according to a recent investigation from the Association of American Medical Colleges (AAMC), by 2034, the nation is predicted to be lacking anywhere from 37,000 to 124,000 medics. This contains a deficit of 17,000 to 48,000 primary care doctors and 3,000 to 13,000 experts, a category that encloses cardiologists.

Segment Analysis

The global peripheral artery disease device market is segmented based on type, device type, end-user and region.

Stent Device Type Expected to Dominate Market

Owing to the increase in the number of product approvals and favorable research outcomes the stents segment will hold the majority of the global market share. For instance, in March 2022, Cordis, a multinational cardiovascular technology corporation, obtained the United States Food and Drug Administration (FDA) clearance for the S.M.A.R.T. RADIANZ Vascular Stent System, a self-expanding stent particularly developed for radial peripheral operations. The RADIANZ Radial Peripheral System is complemented by the recently authorized vascular stent system, BRITE TIP RADIANZ Guiding Sheath, and SABERX RADIANZ PTA Catheter.

Moreover, in October 2021, Boston Scientific Corporation demonstrated promising clinical trial outcomes for the Eluvia Drug-Eluting Vascular Stent System in a clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The Eluvia stent exceeded self-expanding bare metal stents (BMS) for the therapy of patients with peripheral arterial disease (PAD) and superficial femoral artery (SFA) lesions up to 210 mm in length.

Geographical Penetration

Increasing Market Developments in North America

Owing to the presence of key market players in North America holding the majority of the global market share through distinct market tactics. For instance, in September 2021, Abbott, a US-based multinational corporation acquired Walk Vascular, LLC, a medical device corporation with a minimally intrusive mechanical aspiration thrombectomy system developed to remove peripheral blood clots. Walk Vascular's peripheral thrombectomy system is expected to be incorporated into Abbott's existing endovascular product portfolio. The partnership promoted Abbott to expand the scope of its peripheral vascular services.

Likewise, in June 2022, Cardio Flow, Inc., a medical device corporation and manufacturer of minimally invasive peripheral vascular devices for the treatment of peripheral artery disease (PAD), obtained United States Food and Drug Administration (FDA) authorization for the organization's FreedomFlow Peripheral Guidewire.

Similarly, in January 2022, Cook Medical, a US-based corporation obtained breakthrough device designation from the United States Food and Drug Administration (FDA) on a new drug-eluting stent for below the knee (BTK). This novel stent is suggested for the treatment of individuals with limb-threatening persistent ischemia.

COVID-19 Impact Analysis

The COVID-19 pandemic had deep effects on cardio-pulmonary health and healthcare delivery. Direct effects enclosed information on myopericarditis jointly with highly regular information on pneumonia and pulmonary fibrosis, periodically advancing to respiratory collapse and demise. Additionally unpredictable, nevertheless, were the indirect effects of the pandemic on CV examinations and hospital admissions which have repeatedly demonstrated varying drops.

While there has been no indication of actual declines in the preponderance of CVD or the incidence of acute coronary syndromes, these reductions have extended considerations that the pandemic has directed to general under-investigation and under-treatment of many individuals.

Indeed, reports from respective nations suggest substantial declines in investigative procedures for heart failure and coronary and electrophysiological conditions in 2020 corresponded with 2019. Declines in hospital admissions for a degree of CV conditions, including ST-elevation myocardial infarction, have even been registered in the same period.

Russia-Ukraine Impact

The war in Ukraine has caused staggering casualties, an exceptional refugee situation, and devastation of infrastructure including infirmaries and basic needs reserves depletion. The war has even damaged the delivery of medical care. Considerable provincial medical bases have individually documented thousands of trauma case entries from February 2022. The scarcity of dependable air transportation leaves the logistics for health care significantly difficult.

Extreme disturbances to multinational markets generated by Russia's war on Ukraine have revealed susceptibilities to the safety of the supply of raw materials necessary for industrial production. These supply chain exposures are the consequences of export restrictions, bilateral dependences, a deficiency of clarity, and constant market asymmetries, including the engagement of production in only a few nations. For nations influenced by supply chain susceptibilities, there are possibilities to diversify sourcing via extended production and accessing comprehended critical raw materials resources.

By Type

  • Functional Peripheral Artery Disease
  • Organic Peripheral Artery Disease

By Device Type

  • Vascular Stents
  • Balloon Catheters
  • Guidewires
  • Atherectomy Devices
  • Inferior Vena Cava Filters
  • Embolic Protection Devices
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Academic Research Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In June 2023, Surmodics, Inc., a top provider of medical devices and in vitro diagnostic technologies to the healthcare enterprise, obtained U.S. Food and Drug Administration (FDA) clearance for the SurVeil drug-coated balloon (DCB).
  • In June 2023, Endologix lately received FDA authorization for its Detour system to treat long, complex superficial femoropopliteal lesions. The corporation administrators describe the Detour system as a breakthrough in the therapy of peripheral arterial disease (PAD).
  • In February 2023, Abbott entered into a decisive arrangement to acquire Cardiovascular Systems Inc. (CSI), a Minnesota-based healthcare technology corporation concentrated on treating peripheral artery disease (PAD) and coronary artery disease (CAD). The agreement is worth around $890 million.

Competitive Landscape

The major global players in the market include Abbott Laboratories, Boston Scientific Corporation, Becton, Dickinson and Company, Cook, Cordis Corporation, Edward Lifesciences, MicroPort, Terumo Corporation, Medtronic, and Volcano Corporation among others.

Why Purchase the Report?

  • To visualize the global peripheral artery disease device market segmentation based on type, device type, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of peripheral artery disease device market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key product of all the major players.

The global peripheral artery disease device market report would provide approximately 61 tables, 62 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Device Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. High Prevalence of Peripheral Artery Disease
      • 4.1.1.2. Increasing Device Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Availability of Other Treatment Options
      • 4.1.2.2. Cardiologists Workforce Shortage
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. Technology Trend
  • 5.7. End-User Trend
  • 5.8. SWOT Analysis
  • 5.9. Russia-Ukraine War Impact
  • 5.10. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Functional Peripheral Artery Disease*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Organic Peripheral Artery Disease

8. By Device Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 8.1.2. Market Attractiveness Index, By Device Type
  • 8.2. Vascular Stents*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Balloon Catheters
  • 8.4. Guidewires
  • 8.5. Atherectomy Devices
  • 8.6. Inferior Vena Cava Filters
  • 8.7. Embolic Protection Devices
  • 8.8. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Ambulatory Surgical Centers
  • 9.5. Academic Research Centers
  • 9.6. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. EMS Handels Gesellschaft m.b.H.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. BECTON, DICKINSON AND COMPANY
  • 12.3. Medtronic
  • 12.4. Allengers
  • 12.5. EB NEURO S.P.A.
  • 12.6. Shenzhen Delica Medical Equipment Co., Ltd.
  • 12.7. Micromed Group
  • 12.8. NIHON KOHDEN CORPORATION
  • 12.9. Cadwell
  • 12.10. Natus Medical Incorporated

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us